2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2022
Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications
Abu-Alfa A, Atallah P, Azar S, Dagher E, Echtay A, El-Amm M, Hazkial H, Kassab R, Medlej R, Mohamad M. Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Therapy 2022, 14: 11-28. PMID: 36517708, PMCID: PMC9880119, DOI: 10.1007/s13300-022-01340-x.Peer-Reviewed Original ResearchType 2 diabetesGlycemic statusGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsMajor randomized clinical trialsPeptide-1 receptor agonistsCardio-renal benefitsCardio-renal complicationsMultifactorial risk assessmentCotransporter 2 inhibitorsGlucose-lowering agentsIndividualized management planDisease-modifying drugsPrevalence of T2DRandomized clinical trialsPatient's glycemic statusFavorable health outcomesMedical societiesInternational medical societiesScientific Medical SocietiesGlobal health problemAppropriate pharmacological therapyPatient-centered approachLocal medical practiceSuboptimal screeningRecommendations for Preclinical Testing of Treatments Against Alzheimer’s Disease-Related Epileptiform Spikes in Transgenic Rodent Models
Jin N, Babiloni C, Drinkenburg W, Hajós M, Nygaard H, Tanila H. Recommendations for Preclinical Testing of Treatments Against Alzheimer’s Disease-Related Epileptiform Spikes in Transgenic Rodent Models. Journal Of Alzheimer’s Disease 2022, 88: 849-865. PMID: 34092642, DOI: 10.3233/jad-210209.Peer-Reviewed Original ResearchConceptsTransgenic rodent modelsAlzheimer's diseaseRodent modelsPreclinical testingEEG spikesEpileptiform spikesAccelerated disease progressionDisease-modifying drugsRat AD modelClear unmet needSuitable animal modelDiagnosis of epilepsyAD pathologyEpileptiform activityAD patientsDisease progressionMultidisciplinary panelClinical valueDrug interventionAD modelAnimal modelsUnmet needModel rodentsAbnormal levelsDiseaseTreatment effects on event-related EEG potentials and oscillations in Alzheimer's disease
Yener G, Hünerli-Gündüz D, Yıldırım E, Aktürk T, Başar-Eroğlu C, Bonanni L, Del Percio C, Farina F, Ferri R, Güntekin B, Hajós M, Ibáñez A, Jiang Y, Lizio R, Lopez S, Noce G, Parra M, Randall F, Stocchi F, Babiloni C. Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. International Journal Of Psychophysiology 2022, 177: 179-201. PMID: 35588964, DOI: 10.1016/j.ijpsycho.2022.05.008.Peer-Reviewed Original ResearchConceptsAlzheimer's disease dementiaMild cognitive impairmentEvent-related electroencephalographic potentialsDisease dementiaADD patientsFirst disease-modifying drugPlacebo-controlled clinical trialDisease-modifying drugsP300 peak latenciesSymptomatic drugsClinical efficacyClinical trialsCognitive impairmentPatientsAlzheimer's diseaseAbnormal accumulationOlder personsPeak latencyNeurodegenerative disordersAlzheimer's AssociationCognitive functionDementiaElectroencephalographic potentialsExpert panelDisease
2021
Hematopoietic cell transplantation for sickle cell disease: updates and future directions
Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: updates and future directions. Hematology 2021, 2021: 181-189. PMID: 34889368, PMCID: PMC8791142, DOI: 10.1182/hematology.2021000251.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationAlternative donorsCell diseaseOutcomes of HCTHLA-identical related donorsSymptomatic sickle cell diseaseNew disease-modifying drugsHost disease (GVHD) prophylaxisHLA-identical siblingsAvailable therapeutic optionsDisease-modifying drugsLong-term outcomesCord blood expansionConditioning regimensDisease prophylaxisRelated donorsOrgan damageHematopoietic progenitor cellsTherapeutic optionsExcellent outcomesCareful counselingAutologous transplantationClinical registry
2019
Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis
Ciolac D, Luessi F, Gonzalez-Escamilla G, Koirala N, Riedel C, Fleischer V, Bittner S, Krämer J, Meuth S, Muthuraman M, Groppa S. Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis. Frontiers In Immunology 2019, 10: 1779. PMID: 31417557, PMCID: PMC6682686, DOI: 10.3389/fimmu.2019.01779.Peer-Reviewed Original ResearchConceptsCortical atrophyDisease activityMultiple sclerosisDMF groupDeep GM volumesDimethyl fumarate treatmentT-cell depletionDisease-modifying drugsWhite matter damageImmune cell dynamicsDMF therapyNAT patientsStrong CD8Lymphocyte subsetsDisease durationDisease courseMS patientsCell depletionMatter damageLess atrophyFumarate treatmentTreatment paradigmBrain network responsesLesion volumeTherapy response
1995
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Tilley B, Alarcon G, Heyse S, Trentham D, Neuner R, Kaplan† D, Clegg D, Leisen J, Buckley L, Cooper S, Duncan H, Pillemer S, Tuttleman M, Fowler S. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Annals Of Internal Medicine 1995, 122: 81-9. PMID: 7993000, DOI: 10.7326/0003-4819-122-2-199501150-00001.Peer-Reviewed Original ResearchConceptsIgM rheumatoid factor levelsErythrocyte sedimentation rateRheumatoid factor levelsRheumatoid arthritisMinocycline groupGlobal assessmentPlacebo groupMore patientsPlatelet countModified Health Assessment QuestionnaireFactor levelsEfficacy of minocyclineEvaluator's global assessmentWeek 48 visitActive rheumatoid arthritisHealth Assessment QuestionnairePatient global assessmentPlacebo-controlled trialModerate rheumatoid arthritisDisease-modifying drugsMechanism of actionJoint tendernessMorning stiffnessStudy medicationDisease activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply